Harvard Health Columns

Should the FDA Be Tougher on Drug Approvals?

The recent withdrawal of Vioxx from the U.S. market and revelations about problems with several other drugs including Celebrex, Bextra, Strattera and Remicade raise questions about the ability of the U.S. Food and Drug Administration to protect the public health. But is the criticism of the agency fair? …

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In